Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
Top Cited Papers
- 1 July 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (13), 3234-3243
- https://doi.org/10.1200/jco.2001.19.13.3234
Abstract
PURPOSE: To evaluate the safety, pharmacokinetics, and efficacy of a chimeric anti–epidermal growth factor receptor monoclonal antibody, cetuximab, in combination with radiation therapy (RT) in pat...Keywords
This publication has 41 references indexed in Scilit:
- Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and RadiationCancer Biotherapy & Radiopharmaceuticals, 1999
- Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylationOncogene, 1997
- Epidermal Growth Factor Receptor Family and ChemosensitizationJNCI Journal of the National Cancer Institute, 1997
- The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate CarcinomaJournal of Immunotherapy, 1996
- Human Immune Respone to Monoclonal AntibodiesJournal of Immunotherapy, 1994
- Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomasHead & Neck, 1991
- Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trialEuropean Journal of Cancer and Clinical Oncology, 1990
- Expression of Epidermal Growth Factor Receptor in Laryngeal Dysplasia and CarcinomaActa Oto-Laryngologica, 1990
- Quantitation of Mouse Monoclonal Antibody and Human Anti-Mouse Antibody Response in Serum of PatientsHybridoma, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958